Terapia anty-VEGF a obraz angiografii fluoresceinowej u pacjentów z cukrzycowym obrzękiem plamki

• Authors: Katarzyna Mozolewska-Piotrowska , Barbara Nowacka , Wojciech Lubiński

Title variants

EN

Anti-VEGF treatment and fluorescein angiography images in patients with diabetic macular edema

• Languages of publication: PL

Abstracts

EN

Fluorescein angiography enables the appropriate qualification of patients for intravitreal injections, and simplifies decisions connected with treatment modifications during the anti-VEGF therapy. The aim of this paper is to present changes of fluorescein angiography images in the course of the anti-VEGF therapy in patients with DME, and in particular those with diffuse macular edema. Conclusions: 1. Persisted leakage in fluorescein angiography images in patients with DME treated with intravitreal anti-VEGF injections may indicate increased risk of recurrence and the need for further treatment. 2. Anti-VEGF therapy proved to be effective not only in patients with diffuse DME but also in other types of macular edema due to diabetic retinopathy. 3. Anti-VEGF monotherapy in DME does not always prevent progress of retinopathy to proliferative stage, and it does not eliminate the need for laser panphotocoagulation when NV develops.

Keywords

EN

angiografia fluoresceinowa; cukrzycowy obrzęk plamki; terapia anty-VEGF

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Education
• Journal: OphthaTherapy
• Year: 2016
• Volume: 3
• Issue: 3
• Pages: 185-189

Contributors

author

Katarzyna Mozolewska-Piotrowska

• Katedra i Klinika Okulistyki, Pomorski Uniwersytet Medyczny w Szczecinie

author

Barbara Nowacka

• Katedra i Klinika Okulistyki, Pomorski Uniwersytet Medyczny w Szczecinie

author

Wojciech Lubiński

• Katedra i Klinika Okulistyki, Pomorski Uniwersytet Medyczny w Szczecinie

References

• 1. Nguyen QD, Tatlipinar S, Shah SM, et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular oedema. Am J Ophthalmol 2006 142: 961-969.
• 2. Bolz M, Ritter M, Schneider M, et al. A systematic correlation of angiography and high resolution optical coherence tomography in diabetic macular edema. Ophthalmology 2009; 116: 66-72.
• 3. Campochiaro PA, Wykoff CC, Shapiro H, et al. Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema. Ophthalmology 2014; 121: 1783-1789.
• 4. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT Study) 12- month data: raport 2. Ophthalmology 2010; 117: 1107-1118.
• 5. Wells JA, Glassman AR, Jampol LM, et al. Diabetic Retinopathy Clinical Research Network: Aflibercept, bevacizumab or ranibizumab for diabetic macular edema. N Engl J Med 2015; 372: 1193-1203.
• 6. Nguyen QD, Shah SM, Khwaja AA, et al. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology 2007; 114: 1860-1867.
• 7. Cunha-Vaz J, Ashton P, Lezzi R, et al. Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema. Ophthalmology 2014; 121: 1892-1903.
• 8. Sohn HJ, Han DH, Kim TI, et al. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. Am J Ophthalmol 2011; 152: 686-694.

• Document Type: article